LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA’s HIV resistance interpretation system.
ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge® HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient’s details and will support the healthcare providers’ virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.